• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.

作者信息

Matsubayashi Yasuhiro, Yoshida Alkihiro, Suganami Hideki, Oe Momoko, Sato Takaaki, Yaguchi Yuta, Fujihara Kazuya, Yamada Takaho, Tanaka Shiro, Kaku Kohei, Sone Hirohito

机构信息

Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.

Kowa Company, Ltd, Tokyo, Japan.

出版信息

Diabetes Obes Metab. 2022 Dec;24(12):2469-2473. doi: 10.1111/dom.14836. Epub 2022 Sep 12.

DOI:10.1111/dom.14836
PMID:35979908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9825934/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc61/9825934/85123dd98ec2/DOM-24-2469-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc61/9825934/85123dd98ec2/DOM-24-2469-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc61/9825934/85123dd98ec2/DOM-24-2469-g001.jpg

相似文献

1
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.血红蛋白水平及其变化的预测因素，重点关注钠-葡萄糖协同转运蛋白2抑制剂托格列净给药后的贫血和红细胞增多症。
Diabetes Obes Metab. 2022 Dec;24(12):2469-2473. doi: 10.1111/dom.14836. Epub 2022 Sep 12.
2
Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.将二肽基肽酶-4 抑制剂转换为钠-葡萄糖共转运蛋白 2 选择性抑制剂托格列净可改善 2 型糖尿病患者的动脉僵硬度：一项初步研究。
Curr Vasc Pharmacol. 2019;17(4):411-420. doi: 10.2174/1570161116666180515154555.
3
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.新型钠-葡萄糖协同转运蛋白2抑制剂托格列净单药治疗日本2型糖尿病患者的疗效和安全性：一项2期和3期联合随机、安慰剂对照、双盲、平行组比较研究。
Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65.
4
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.估计的血浆体积与钠-葡萄糖共转运蛋白 2 抑制剂托格列净长期给药和随后停药后体重减轻的相关性。
Diabetes Obes Metab. 2021 Jul;23(7):1660-1665. doi: 10.1111/dom.14387. Epub 2021 May 4.
5
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.托格列净可降低体脂量，并改善外周胰岛素抵抗。
Diabetes Obes Metab. 2018 May;20(5):1311-1315. doi: 10.1111/dom.13211. Epub 2018 Feb 4.
6
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.心力衰竭风险分层与钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的疗效。
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
7
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.托格列净是一种钠-葡萄糖协同转运蛋白2的选择性抑制剂，可抑制KKAy/Ta小鼠（肥胖型2型糖尿病动物）的肾脏损伤。
Diab Vasc Dis Res. 2016 Nov;13(6):438-441. doi: 10.1177/1479164116657304. Epub 2016 Jul 12.
8
The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.钠-葡萄糖共转运蛋白 2 抑制剂（托格列净）对无蛋白尿糖尿病患者肾小管损伤的影响。
Int Urol Nephrol. 2022 Aug;54(8):1907-1914. doi: 10.1007/s11255-021-03064-6. Epub 2021 Nov 29.
9
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.托格列净，一种强效且高度特异的钠/葡萄糖共转运蛋白 2 抑制剂，可改善糖尿病大鼠和小鼠的血糖控制。
J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. doi: 10.1124/jpet.112.191593. Epub 2012 Mar 12.
10
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.与钠-葡萄糖协同转运蛋白2抑制剂治疗相关的JAK2野生型红细胞增多症。
Blood. 2021 Dec 30;138(26):2886-2889. doi: 10.1182/blood.2021013996.

引用本文的文献

1
Impact of Albuminuria and Renal Dysfunction on the Anemia-Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real-World Observational Study.蛋白尿和肾功能不全对2型糖尿病患者中SGLT2抑制剂改善贫血作用的影响：一项真实世界观察性研究
J Diabetes Res. 2025 Jun 28;2025:5399360. doi: 10.1155/jdr/5399360. eCollection 2025.
2
Effect of Baseline Values of Renal Prognosis-related Factors on Their Changes after Initiating Tofogliflozin Treatment: A Retrospective Study in Japanese Patients with Type 2 Diabetes and Renal Impairment.肾脏预后相关因素的基线值对托格列净治疗开始后其变化的影响：一项针对日本2型糖尿病合并肾损伤患者的回顾性研究
JMA J. 2024 Oct 15;7(4):571-579. doi: 10.31662/jmaj.2024-0128. Epub 2024 Sep 6.

本文引用的文献

1
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.非酒精性脂肪性肝病、内脏性肥胖与2型糖尿病的代谢三联征：对治疗的启示
Diabetes Obes Metab. 2022 Feb;24 Suppl 2:15-27. doi: 10.1111/dom.14651. Epub 2022 Jan 24.
2
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.与钠-葡萄糖协同转运蛋白2抑制剂治疗相关的JAK2野生型红细胞增多症。
Blood. 2021 Dec 30;138(26):2886-2889. doi: 10.1182/blood.2021013996.
3
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
恩格列净对 2 型糖尿病患者红细胞生成的影响：一项随机、安慰剂对照研究的数据。
Diabetes Obes Metab. 2021 Dec;23(12):2814-2818. doi: 10.1111/dom.14517. Epub 2021 Aug 25.
4
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.比较托格列净和吡格列酮在 2 型糖尿病合并非酒精性脂肪性肝病患者中的疗效（ToPiND 研究）：一项随机前瞻性开放标签对照试验。
BMJ Open Diabetes Res Care. 2021 Feb;9(1). doi: 10.1136/bmjdrc-2020-001990.
5
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.卡格列净对 2 型糖尿病合并慢性肾脏病患者贫血的影响：来自 CREDENCE 试验的事后分析。
Lancet Diabetes Endocrinol. 2020 Nov;8(11):903-914. doi: 10.1016/S2213-8587(20)30300-4.
6
Association between hemoglobin levels and non-alcoholic fatty liver disease in patients with young-onset type 2 diabetes mellitus.血红蛋白水平与青年 2 型糖尿病患者非酒精性脂肪肝的相关性。
Endocr J. 2020 Nov 28;67(11):1139-1146. doi: 10.1507/endocrj.EJ20-0071. Epub 2020 Jul 17.
7
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.卡格列净对2型糖尿病患者肾脏保护作用的介导因素。
Kidney Int. 2020 Sep;98(3):769-777. doi: 10.1016/j.kint.2020.04.051. Epub 2020 May 27.
8
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.2016 年世界卫生组织（WHO）髓系增殖性肿瘤分类和诊断标准：文件摘要和深入讨论。
Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y.
9
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.托格列净可降低体脂量，并改善外周胰岛素抵抗。
Diabetes Obes Metab. 2018 May;20(5):1311-1315. doi: 10.1111/dom.13211. Epub 2018 Feb 4.
10
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.恩格列净如何降低心血管死亡率？来自 EMPA-REG OUTCOME 试验中介分析的见解。
Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.